180869-38-9 Usage
General Description
2-(Methylamino)pyrimidine-4-carboxaldehyde dimethyl acetal is a chemical compound with the molecular formula C8H12N2O2. 2-(METHYLAMINO)PYRIMIDINE-4-CARBOXALDEHYDE DIMETHYL ACETAL is a dimethyl acetal derivative of 2-(methylamino)pyrimidine-4-carboxaldehyde and is commonly used as a reagent in organic synthesis. It is a colorless liquid with a strong fruity odor, and it is mainly employed as an intermediate in the production of pharmaceuticals, agrochemicals, and other fine chemicals. Its main applications include its use as a reagent for the synthesis of heterocyclic compounds and as a key building block in the production of various chemical compounds. It is important to handle this compound with caution, as it can be harmful if ingested, inhaled, or absorbed through the skin, and appropriate safety measures should be taken when handling or using this chemical.
Check Digit Verification of cas no
The CAS Registry Mumber 180869-38-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,0,8,6 and 9 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 180869-38:
(8*1)+(7*8)+(6*0)+(5*8)+(4*6)+(3*9)+(2*3)+(1*8)=169
169 % 10 = 9
So 180869-38-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H13N3O2/c1-9-8-10-5-4-6(11-8)7(12-2)13-3/h4-5,7H,1-3H3,(H,9,10,11)
180869-38-9Relevant articles and documents
HETEROCYCLIC COMPOUNDS USED AS FGFR INHIBITORS
-
Paragraph 0174-0176, (2019/05/24)
The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the same, a preparation method thereof, and use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The compound is a heterocyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, prodrug, solvent compound, polymorph, isomer or stable isotopic derivative thereof. The present invention further relates to use of the compound for the treatment or prevention of related diseases which are FGFR-mediated such as cancer, and a method for applying the compound to treat said diseases.
8-HETEROARYLPURINE MNK2 INHIBITORS FOR TREATING METABOLIC DISORDERS
-
Page/Page column 37-38, (2010/11/28)
This invention relates to 8-Heteroarylpurine Mnk2 Inhibitors which are useful for the treatment and prevention of metabolic disorders such as obesity and diabetes.
INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IκB KINASE
-
Page/Page column 18-19, (2010/11/30)
The invention relates to compounds of formula (I). Said compounds are suitable for producing medicaments for the prophylaxis and treatment of diseases, the progression of which involves increased activity of IκB kinase.